Olopatallerg, eye drops 0.1% 5 ml
€15.77 €13.14
Increased tear production, Red eyes, Allergic conjunctivitis, Allergy, PollinosisTreatment of symptoms of seasonal allergic conjunctivitis.
Active ingredient
Olopatadine
Composition
1 ml – olopatadine hydrochloride 1.1 mg, which corresponds to the content of olopatadine 1 mg.
Interaction
Studies of interaction of olopatadine with other drugs have not been conducted.
Directions for use
Topically.
Push 1 drop into the conjunctival sac of the affected eye twice a day (8 hours apart).
The duration of treatment is up to four months.
If necessary, the drug can be used in combination with other drugs. In this case, the interval between their application should be at least 5 minutes.
Elderly people.
There is no need to adjust doses for elderly patients.
Children from 3 years of age.
Olopatallerg can be used in the same doses as in adults.
Renal or hepatic impairment
There have been no studies in patients with renal or hepatic impairment regarding the administration of Olopatadine in the form of eye drops. However, it is not expected that dose adjustments will be necessary in patients with renal or hepatic impairment.
Do not touch the tip of the vial to the eyelids, periorbital skin, or other surfaces to avoid microbial contamination of the drug. Close the cap tightly after use.
Special Instructions
Olopatadine hydrochloride is an anti-allergic/antihistamine drug for topical use in ophthalmology, and despite local use, it can be absorbed into the systemic bloodstream. If pronounced hypersensitivity reactions occur, the drug should be discontinued.
The drug contains benzalkonium chloride, which may be adsorbed by soft contact lenses and irritate the eyes. Contact lenses should be removed before instillation and inserted again not earlier than 15 minutes after instillation.
With frequent or prolonged use, benzalkonium chloride may cause pitting keratitis or toxic ulcerative keratopathy in patients with dry eye syndrome or corneal pathology.
Olopatadine has no significant effect on the ability to operate vehicles, machinery. If blurred vision is noted immediately after instillation, it is necessary to wait until visual clarity is restored before driving vehicles and mechanisms.
.
Contraindications
Hypersensitivity to the drug components, pregnancy and breastfeeding, age under 3 years.
In patients with concomitant dry eye syndrome and corneal diseases.
.
Side effects
General information on the profile of adverse events
In clinical trials involving 1680 patients the dosing regimen was 1 to 4 drops per day, the duration of therapy was up to 4 months, and olopatadine was used both in monotherapy and together with loratadine in a dose of 10 mg. The overall incidence of adverse events was about 4.5%, while discontinuation of participation in a clinical trial due to adverse reactions was noted only in 1.6% of cases. No serious adverse events were observed in the clinical trials, either in the visual organ or in the body as a whole. The most frequent adverse reaction associated with the treatment was discomfort in the eye, this phenomenon was noted in 0.7% of patients.
Table data on adverse events
The following adverse events were observed during clinical studies and post-registration use of the drug and are classified according to the following frequency of adverse events: Very common (≥1/10), common (≥1/100 to <1/10), infrequent (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), frequency unknown (incidence cannot be determined based on available data). Within each group, adverse events are listed in decreasing order of severity.
System-organ class | Frequency of occurrence < | Undesirable events | |
Infectious disorders | Infrequent | Rhinitis | |
Immune system disorders | Frequency unknown | Hypersensitivity to drug components, facial swelling | |
Nervous system disorders | Often | Headache, dysgeusia < | |
Infrequent | Dizziness, hypoesthesia | ||
Frequency unknown | Sleepiness | ||
Visual disturbances | Often | Pain in the eye, eye irritation, “dry” eye syndrome, unusual sensations in the eye. | |
Infrequent | Corneal erosion, corneal epithelial defect, pitting keratitis, keratitis, accumulation of pigment in area of corneal defect during diagnostic testing, ocular discharge, photophobia, blurred vision, decreased visual acuity, blepharospasm, ocular discomfort, ocular itching, conjunctival folliculosis, conjunctival disorders, feeling of a foreign body in the eye, lacrimation, erythema of the eyelids, eyelid edema, eyelid disorders, conjunctival injection. | ||
Frequency unknown | Corneal edema, conjunctival edema, conjunctivitis, mydriasis, visual impairment, crusts on the edges of the eyelids. | ||
Respiratory, thoracic and mediastinal disorders | Often | Nasal dryness | |
Infrequent unknown | Dyspnea, sinusitis | ||
Gastrointestinal disorders | Frequency unknown /p> | Nausea, vomiting | |
Skin and subcutaneous fatty tissue disorders | Infrequent | Contact dermatitis, sensation of burning skin, dry skin. | |
Frequency unknown | Dermatitis, erythema. | ||
General disorders | Frequent | | |
Frequency unknown | Asthenia, malaise |
In very rare cases, corneal calcification developed when phosphate-containing drops were used by patients with concomitant significant corneal damage.
Overdose
There are no reports of toxic effects from accidental injection of excessive amounts of the drug into the conjunctival cavity or accidental ingestion. If an overdose develops from accidental ingestion, treatment should be supportive.
Pregnancy use
Fertility
There have been no studies on the effect of topical use of Olopatadine in ophthalmology on human fertility.
Pregnancy
There are no or limited data on topical use of olopatadine in ophthalmology in pregnant women. Animal studies have reported toxic effects of olopatadine on reproductive function when used systemically. The use of olopatadine during pregnancy and by women of childbearing age who do not use contraception is not recommended.
Breast-feeding period
Olopatadine has been noted to be excreted into the breast milk when using the drug in animals. The risk to newborns and infants cannot be excluded. It is not recommended to use the drug Olopataller during breastfeeding.
Similarities
Opatanol, Visallergol
Weight | 0.050 kg |
---|---|
Shelf life | 3 years. After opening the bottle the drops should be used within 4 weeks. Do not use after the expiration date! |
Conditions of storage | In the dark place at a temperature not exceeding 25 °С. Store out of the reach of children. |
Manufacturer | C.O.Rompharm Company S.R.L., Romania |
Medication form | eye drops |
Brand | C.O.Rompharm Company S.R.L. |
Related products
Buy Olopatallerg, eye drops 0.1% 5 ml with delivery to USA, UK, Europe and over 120 other countries.